Status:
RECRUITING
Cerebrospinal Fluid Biomarkers for Brain Tumors
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Central Nervous System Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of c...
Detailed Description
PRIMARY OBJECTIVE: I. To collect cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discovery in patients with gliomas. SECONDARY OBJECTIVE: I. Ev...
Eligibility Criteria
Inclusion
- Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures
- Subjects must be 18 years of age or older
Exclusion
- Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study
- Pregnant women or women who may be pregnant are specifically excluded from study participation
- Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available
- Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded
- Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded
- Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access
Key Trial Info
Start Date :
January 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04692324
Start Date
January 14 2021
End Date
December 31 2028
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905